» Articles » PMID: 25153686

AHNAK KO Mice Are Protected from Diet-induced Obesity but Are Glucose Intolerant

Overview
Journal Horm Metab Res
Specialty Endocrinology
Date 2014 Aug 26
PMID 25153686
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

AHNAK is a 700 KD phosphoprotein primarily involved in calcium signaling in various cell types and regulating cytoskeletal organization and cell membrane architecture. AHNAK expression has also been associated with obesity. To investigate the role of AHNAK in regulating metabolic homeostasis, we studied whole body AHNAK knockout mice (KO) on either regular chow or high-fat diet (HFD). KO mice had a leaner phenotype and were resistant to high-fat diet-induced obesity (DIO), as reflected by a reduction in adipose tissue mass in conjunction with higher lean mass compared to wild-type controls (WT). However, KO mice exhibited higher fasting glucose levels, impaired glucose tolerance, and diminished serum insulin levels on either diet. Concomitantly, KO mice on HFD displayed defects in insulin signaling, as evident from reduced Akt phosphorylation and decreased cellular glucose transporter (Glut4) levels. Glucose intolerance and insulin resistance were also associated with changes in expression of genes regulating fat, glucose, and energy metabolism in adipose tissue and liver. Taken together, these data demonstrate that (a) AHNAK is involved in glucose homeostasis and weight balance (b) under normal feeding KO mice are insulin sensitive yet insulin deficient; and (c) AHNAK deletion protects against HFD-induced obesity, but not against HFD-induced insulin resistance and glucose intolerance in vivo.

Citing Articles

Systematic functional characterization of non-coding regulatory SNPs associated with central obesity.

Dong S, Duan Y, Zhu R, Jia Y, Chen J, Huang X Am J Hum Genet. 2025; 112(1):116-134.

PMID: 39753113 PMC: 11739881. DOI: 10.1016/j.ajhg.2024.11.005.


Multi-Omics Analysis Revealed the rSNPs Potentially Involved in T2DM Pathogenic Mechanism and Metformin Response.

Damarov I, Korbolina E, Rykova E, Merkulova T Int J Mol Sci. 2024; 25(17).

PMID: 39273245 PMC: 11394919. DOI: 10.3390/ijms25179297.


Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis.

Padovani-Claudio D, Ramos C, Capozzi M, Penn J Prog Retin Eye Res. 2023; 94:101151.

PMID: 37028118 PMC: 10683564. DOI: 10.1016/j.preteyeres.2022.101151.


Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.

Zhang Z, Yu Y, Li P, Wang M, Jiao W, Liang Y Front Immunol. 2022; 13:954616.

PMID: 35958586 PMC: 9359097. DOI: 10.3389/fimmu.2022.954616.


The Obscure Potential of AHNAK2.

Zardab M, Stasinos K, Grose R, Kocher H Cancers (Basel). 2022; 14(3).

PMID: 35158796 PMC: 8833689. DOI: 10.3390/cancers14030528.